"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

What's new at I-SPY?

I-SPY 2 TRIAL featuring three abstracts at ASCO's 2018 Annual Meeting

Announcement

May 30, 2018

Dr. Laura Esserman Honored: OncLive® To Induct the 2018 Class of Giants of Cancer Care®

Announcement

May 26, 2018

Dr. Laura Esserman recognized as a 2018 Fellow of the American Society of Clinical Oncology (FASCO)

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY2 platform trial for neoadjuvant treatment of locally advanced breast cancer.

1300

patients enrolled

13

agents completed
evaluation since 2010

3

agents received
accelerated approval

World-class science requires world-class scientists

Meet some of our team

Special Advisor

National Cancer Institute

Medical Oncologist

University of Chicago

Bioinformatician

University of California, San Francisco

Breast Cancer Advocate

Biomarkers, UCSF Breast Science Advocacy

Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

I-SPY is supported by: